id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S7660 R22660 |
Tomson (Phenobarbital), 2018 | Hypospadias | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.43 [0.17;11.89] C | 1/294 6/2,514 | 7 | 294 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5941 R23803 |
Hernández-Díaz (Phenobarbital) (Controls exposed to Lamotrigine, sick), 2012 | Hypospadias | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No Controls: mixed indications | 23.72 [0.96;584.27] C | 1/199 0/1,562 | 1 | 199 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6500 R17856 |
Bànhidy (Phenobarbital), 2011 | Hypospadias | throughout pregnancy | case control | unexposed, sick | Adjustment: No Matched | 3.80 [0.06;243.53] C | 0/ 3/13 | 3 | 0 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6686 R18617 |
D'Souza (Phenobarbital) (Controls unexposed, disease free), 1991 | Hypospadias | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
17.57 [0.30;1024.08] C excluded (control group) |
0/4 0/62 | 0 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6694 R18778 |
D'Souza (Phenobarbital) (Controls unexposed, sick), 1991 | Hypospadias | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 2.14 [0.03;131.94] C | 0/4 0/8 | 0 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5526 R19276 |
Van der Pol (Phenobarbital) (Controls unexposed, disease free), 1991 | Hypospadias | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
4.74 [0.09;251.42] C excluded (control group) |
0/12 0/55 | 0 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6824 R19326 |
Van der Pol (Phenobarbital) (Controls unexposed, sick), 1991 | Hypospadias | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 1.87 [0.03;100.54] C | 0/12 0/22 | 0 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 5 studies | 3.00 [0.73;12.35] | 11 | 509 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Phenobarbital; 2: Phenobarbital) (Controls exposed to Lamotrigine, sick; 3: Phenobarbital; 4: Phenobarbital) (Controls unexposed, sick; 5: Phenobarbital) (Controls unexposed, sick;
Asymetry test p-value = 0.5966 (by Egger's regression)
slope=-0.0817 (2.0831); intercept=0.7615 (1.2904); t=0.5901; p=0.5966
excluded 6686, 5526